Zhenhua Hu

Zhenhua Hu

Auto-generated profile, based on publicly available information

Zhenhua Hu

Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2012 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SGSong Gao
Song Gao
XZXiaoyun Zhao
Xiaoyun Zhao
BLBei Lin
Bei Lin
ZHZhenhua Hu
Zhenhua Hu
LYLimei Yan
Limei Yan
JGJian Gao
Jian Gao

15 October 2021 in Stem Cells International
Verified
Journal Article
Open access
PDF file
YLYixuan Low
Yixuan Low
DTDennis Eng Kiat Tan
Dennis Eng Kiat Tan
ZHZhenhua Hu
Zhenhua Hu
STShawn Ying Xuan Tan
Shawn Ying Xuan Tan
WTWee-Wei Tee
Wee-Wei Tee
Transposable elements (TEs) are mobile genetic sequences capable of duplicating and reintegrating at new regions within the genome. A growing body of evidence has demonstrated that these elements play important roles in host genome evolution, despite being traditionally viewed as parasitic elements. To prevent ectopic activation of TE transposition and transcription, they are epigenetically silenced in most somatic tissues. Intriguingly, a specific class of TEs—retrotransposons—is transiently expressed at discrete phases during mammalian development and has been linked to the establishment of totipotency during zygotic genome activation (ZGA). While mechanisms controlling TE regulation in somatic tissues have been extensively studied, the significance underlying the unique transcriptional reactivation of retrotransposons during ZGA is only beginning to be uncovered. In this review, we summarize the expression dynamics of key retrotransposons during ZGA, focusing on findings from in vivo totipotent embryos and in vitro totipotent-like embryonic stem cells (ESCs). We then dissect the functions of retrotransposons and discuss how their transcriptional activities are finetuned during early stages of mammalian development.

4 November 2026 in Cancer Research
Verified
Journal Article
Closed access
JLJingyao Lian
Jingyao Lian
WLWenshu Li
Wenshu Li
GZGe Zhao
Ge Zhao
SLShiying Li
Shiying Li
TLTianqi Li
Tianqi Li
SZShuang Zhang
Shuang Zhang
Epigenetic dysregulation plays a vital role in the progression of endometrial cancer, yet targeted treatment options remain limited. In this study, we identified the histone acetyltransferase KAT5 as a therapeutic target in endometrial cancer. KAT5 was significantly overexpressed in endometrial cancer and correlated with poor patient outcomes. Silencing KAT5 inhibited endometrial cancer cell proliferation and tumor growth. KAT5-deficient endometrial cancer cells exhibited impaired cytoskeletal dynamics, leading to heightened DNA damage and increased micronuclei formation. The release of micronuclear DNA into the cytoplasm activated the cGAS–STING pathway, thereby amplifying proinflammatory immune responses. Mechanistically, KAT5 acetylated H2A.Z to transcriptionally activate Arp2/3 complex genes, promoting actin polymerization and chromosomal stability. Inhibition of Arp2/3 or depletion of its subunit ARPC5 replicated the effects of KAT5 loss, whereas restoring ARPC5 mitigated chromosomal instability and cGAS activation. In transplantation models of endometrial cancer cell lines and syngeneic murine Trp53−/−;Pten−/− endometrial cancer organoids, pharmacologic inhibition of KAT5 with NU9056 suppressed tumor progression and enhanced immune cell infiltration. NU9056 also induced Arp2/3 disruption, genomic instability, and cGAS–STING activation in patient-derived organoids from clinical endometrial cancer samples. Together, these findings highlight KAT5 as a promising therapeutic target in endometrial cancer that influences chromatin remodeling, cytoskeletal dynamics, and immune modulation. Significance: KAT5 is an oncogenic epigenetic driver of endometrial cancer that induces H2A.Z acetylation-mediated Arp2/3 activation to promote progression and immune evasion, providing a strong rationale for developing KAT5-targeted dual anti-tumor/immunotherapeutic strategies.